PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07K 14/18, A61K 39/29, C07K 16/10, G01N 33/576 — A1

(11) International Publication Number: **WO 99/67285**

(43) International Publication Date: 29 December 1999 (29.12.99)

(21) International Application Number: PCT/EP99/04342

(22) International Filing Date: 23 June 1999 (23.06.99)

(30) Priority Data:

98870142.1	24 June 1998 (24.06.98)	EP
99870033.0	22 February 1999 (22.02.99)	EP

(71) Applicant *(for all designated States except US)*: INNOGENETICS N.V. [BE/BE]; Industriepark Zwijnaarde 7, P.O. Box.4, B–9052 Ghent (BE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: DEPLA, Erik [BE/BE]; Burgstraat 58, B–9070 Destelbergen (BE). MAERTENS, Geert [BE/BE]; Zilversparrenstraat 64, B–8310 Brugge (BE). BOSMAN, Alfons [BE/BE]; Hulst 165, B–1745 Opwijk (BE). VAN WIJNENDAELE, Frans [BE/BE]; Zomerstraat 46, B–9270 Laarne (BE).

(74) Common Representative: INNOGENETICS N.V.; Industriepark Zwijnaarde 7, P.O. Box 4, B–9052 Ghent (BE).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: PARTICLES OF HCV ENVELOPE PROTEINS: USE FOR VACCINATION

(57) Abstract

The present invention is based on the finding that the envelope proteins of HCV induce a beneficial immune response in chronically HCV–infected chimpanzees. The immunization can preferentially be carried out using HCV envelope proteins in the form of particles which are produced in a detergent–assisted manner. The envelope proteins when presented as such to chronic HCV carriers are highly immunogenic and stimulate both the cellular and humoral immune response.